STOCKS TELEGRAPH

Tag: Dare Bioscience Inc.

  • Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Daré Bioscience, Inc. (NASDAQ: DARE) shares surged by 74.16% to $4.38 as of the last check during morning trading following the release of encouraging interim data from a Phase 3 clinical trial.

    Positive Interim Analysis Supports Efficacy and Safety

    The trial evaluates the contraceptive effectiveness, safety, and acceptability of Ovaprene, DARE’s investigational monthly, hormone-free intravaginal contraceptive. Notably, no FDA-approved products currently exist within this contraceptive category, placing Ovaprene in a potentially groundbreaking position.

    The study’s Data Safety Monitoring Board (DSMB) conducted a planned interim review and recommended that the trial continue without any modifications. The interim analysis revealed that approximately 9% of women using Ovaprene experienced pregnancy—aligned with prior expectations and data from the pre-pivotal postcoital test study. The effectiveness of ovaprene as a hormone-free contraception is well supported by these studies.

    Crucially, during the review, no significant safety issues were brought forward. Vaginal odor was the most frequent product-related adverse event, causing almost 17% of participants to stop the research. Overall tolerability remained acceptable in spite of this, and most women who finished the experiment had a high propensity to use Ovaprene if it were made commercially accessible.

    A New Direction for Women’s Health

    Ovaprene has the potential to address a significant unmet need in the contraceptive market, according to Daré Bioscience, which expressed confidence about these findings. The business sees Ovaprene as a potentially game-changing solution in reproductive health, given the rising desire among American women for hormone-free birth control solutions.

    Commercial Prospects with Bayer and Future Milestones

    Commercial momentum may accelerate if Bayer elects to exercise its exclusive U.S. commercialization rights following trial completion. This decision would involve a $20 million payment to Daré Bioscience.

    In total, Daré Bioscience stands to gain up to $310 million in commercial milestone payments, along with double-digit tiered royalties on net sales. These payments are subject to a minority interest provision under a royalty purchase agreement made in April 2024.

  • What Explains The 61% Rise In DARE Stock Premarket?

    What Explains The 61% Rise In DARE Stock Premarket?

    Shares of Daré Bioscience Inc. (DARE) were up 61.18% in pre-market trading as of the last check at $2.45. In yesterday’s session, shares of DARE dropped -3.90% at $1.52. DARE stock fluctuated between $1.46 and $1.60 during the day. There were 3.19 million shares traded, which is above DARE’s daily volume of 2.47 million over the last 50 days and its year-to-date volume of 2.55 million.

    Shares of DARE stock have gained 50.50% in the last 12 months, but have declined -9.52% in the last week. For the past six months, DARE stocks have gained 16.03%, and for the past three months, the stock has declined -11.11%. DARE stock’s returns for this year have been 13.43%.  DARE’s stock rose despite no current news, and we can then identify recent developments for a deeper analysis.

    What happened recently at DARE?

    Daré Bioscience develops innovative products for women’s health as a clinical-stage biopharmaceutical company. As part of its mission, DARE brings to market a wide range of differentiated therapies for women debating contraception, vaginal health, sexual health, and fertility.

    The Phase 1 clinical trial of DARE-HRT1 by Daré Bioscience recently reported positive topline results.

    • DARE-HRT1 is a new IVR technology that delivers bio-identical 17-estradiol and bio-identical progesterone continuously for 28 days as part of a hormone therapy (HT) regimen to treat vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
    • Two different active pharmaceutical ingredients were successfully delivered by DARE-HRT1 reliably over 28 days.
    • It is a great achievement for Daré and for the IVR platform to generate positive topline data in its first Phase 1 study utilizing novel IVR technology.
    • The use of hormone therapy for some women can relieve symptoms of menopause such as hot flashes and vaginal dryness while also preventing bone loss.
    • The North American Menopause Society’s guidance on hormone therapy includes that dosing estrogen and progestogen in combination may offer important benefits to women and NAMS observed that non-oral routes of administration may offer advantages over orally administered therapies.

    What DARE study has demonstrated?

    Daré Bioscience (DARE) is encouraged by the Phase 1 results since these data demonstrate DARE-HRT1’s ability to meet its dual release objectives. IVR technology played a big role in DARE-HRT1’s success as it provides hormone therapy as well as platform technology. Compared to current vaginal drug delivery solutions, Dare-HRT1’s IVR technology may offer a more flexible and convenient way to deliver drugs to women as it allows them to release one or more drugs at a desired rate over time and at their convenience as well.

  • 30 hot stocks trending in the pre-market session

    Naked Brand Group Limited (NAKD) stock plunged -4.92% to $0.1603 in the pre-market trading.

    Nano Dimension Ltd. (NASDAQ: NNDM)  shares are trading up 11.74% at $4.95 at the time of writing recently announced prices $100 million registered direct offering. Company’s 52-week ranged between $0.51 to $6.00. Analysts have a consensus price target of $8.

    BIO-key International Inc. (BKYI), a Security & Protection Services company, dropped about -6.14% at $2.75 in pre-market trading Monday after company recently announced that the Board of Directors has approved a 1-for-8 reverse stock split that is expected to become effective on November 20, 2020.

    Eiger BioPharmaceuticals Inc. (EIGR) stock moved up 9.67 percent to $11.0 in the pre-market trading following firm recently revealed that the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).

    Lexicon Pharmaceuticals Inc. (LXRX) is down more than -5.33% at $1.42 in pre-market hours Monday November 23, 2020. The stock had dropped over -3.23% to $1.50 in the last trading session.

    Despegar.com Corp. (DESP), a Travel Services company, dropped about -6.54% at $10.01 in pre-market trading Monday.

    Bristol-Myers Squibb Company (BMY) stock moved up 1.41 percent to $62.48 in the pre-market trading today following announcement of  a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.

    Niu Technologies (NIU) lost over -5.79% at $33.66 in pre-market trading Monday November 23, 2020 as the firm revealed changes to its board of directors and committees of the Board.

    Nxt-ID Inc. (NXTD) is up more than 8.36% at $0.389 in pre-market hours Monday November 23, 2020. The stock had dropped over -0.28% to $0.36 in the last trading session following the corporation said that it plans to adjourn the Annual Meeting of Stockholders, scheduled to be held on Monday, November 23, 2020 at 9:00 a.m. (Eastern Time), to Tuesday, November 24, 2020 at 9:00 a.m. (Eastern Time), to be held at the Company’s office at 288 Christian Street, Hangar C 2nd Floor, Oxford CT 06478.

    Before the trading started on November 23, 2020, Verb Technology Company Inc. (VERB) is up 9.26% to reach $1.18. It has been trading in a 52-week range of $0.78 to $2.64.

    CIIG Merger Corp. (CIIC) stock soared 13.29% to $19.26 in the pre-market trading.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) shares are trading up 8.89% at $9.8 at the time of writing. Company’s 52-week ranged between $3.26 to $11.35 after announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy.

    Xunlei Limited (XNET) gained over 12.0% at $3.08 in pre-market trading Monday November 23, 2020.

    Amarin Corporation plc (AMRN) is down more than -9.74% at $4.17 in pre-market hours Monday November 23, 2020 after shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of VASCEPA® (icosapent ethyl) conducted in China by Amarin partner, Edding. The stock had jumped over 1.76% to $4.62 in the last trading session.

    United Microelectronics Corporation (UMC) grew over 8.65% at $6.28 in pre-market trading today.

    Baozun Inc. (BZUN), a Internet Retail company, dropped about -4.82% at $39.9 in pre-market trading Monday. The firm today announced that its Board of Directors has appointed Mr. Arthur Yu, the Company’s current Vice President of Finance, as Chief Financial Officer (“CFO”), effective December 1, 2020.

    Pioneer Power Solutions Inc. (PPSI) stock moved up 10.49 percent to $4.32 in the pre-market trading.

    SPI Energy Co. Ltd. (SPI) gained over 8.79% at $10.4 in pre-market trading Monday November 23, 2020.

    Bio-Path Holdings Inc. (BPTH) is down more than -0.54% at $3.65 in pre-market hours Monday November 23, 2020 as a result of announcement that the enrollment and dosing of the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients. The stock had jumped over 9.88% to $3.67 in the last trading session.

    Before the trading started on November 23, 2020, Fuel Tech Inc. (FTEK) is up 19.69% to reach $1.52. It has been trading in a 52-week range of $0.30 to $2.05.

    Medigus Ltd. (MDGS) stock soared 8.48% to $3.07 in the pre-market trading after the firm announced its intention to enter into the electric vehicle and electric charging markets. Medigus signed a non-binding memorandum of understanding with the founders of EMuze to invest in a joint venture, NewCo, for the commercialization of EV micro-mobility vehicles for individual urban use, “last mile” and cargo delivery.

    GreenPower Motor Company Inc. (NASDAQ: GP) shares are trading up 11.34% at $24.54 at the time of writing as the news appeared that the Company has granted an aggregate of 300,000 incentive stock options with 100,000 stock options to each of Brendan Riley, Michael Sieffert and Fraser Atkinson. The stock options are subject to the approval of the TSX Venture Exchange and are exercisable for a period of five years at a price of US $20 per share. Company’s 52-week ranged between $0.82 to $23.45. Analysts have a consensus price target of $22.

    Check-Cap Ltd. (CHEK) grew over 7.1% at $0.38 in pre-market trading today.

    Mesoblast Limited (MESO), a Biotechnology company, rose about 9.8% at $15.13 in pre-market trading Monday after announcement of financial results for the third quarter and nine months ended September 30, 2020

    Titan Pharmaceuticals Inc. (TTNP) stock moved down -5.62 percent to $0.193 in the pre-market trading.

    The9 Limited (NCTY) gained over 21.45% at $3.68 in pre-market trading Monday November 23, 2020 as the company revealed that it will hold its annual general meeting of shareholders at the 17 Floor, No. 130 Wu Song Road, Hong Kou District, Shanghai 200080, People’s Republic of China on December 22, 2020 at 2:00 p.m., Shanghai time.

    Before the trading started on November 23, 2020, CPS Technologies Corporation (CPSH) is up 30.0% to reach $3.12. It has been trading in a 52-week range of $0.88 to $3.35.

    Canaan Inc. (CAN) stock soared 17.52% to $5.03 in the pre-market trading following the company plans to release its third quarter 2020 financial results before the market opens on Monday, November 30, 2020.

    Ferroglobe PLC (GSM), a Other Industrial Metals & Mining company, rose about 24.46% at $1.16 in pre-market trading Monday.

    Ideanomics Inc. (IDEX) stock moved up 37.01 percent to $2.11 in the pre-market trading after the company announced that it has increased its stake in California-based Solectrac, Inc. through a follow-on investment of an additional $1.3 million.